🤖 This page was written by AI and reviewed by a human. 2026-07-14. Version 0.18
Shanshan Zhong
Status
Born in 1954 (age –). Living in Hangzhou, China.
Criminal status: No personal convictions
Summary
Zhong Shanshan (born 1954) is the founder and chairman of Nongfu Spring, China's largest bottled water and beverage company, and the controlling shareholder of Wantai BioPharmaceutical, a Beijing-based vaccine and diagnostics maker. Both companies listed publicly in Hong Kong in 2020, and as of July 2026 Zhong's fortune stands at USD 58.6 billion, ranking #33 on Forbes' Real-Time Billionaires list.
Nongfu Spring posted first-half 2025 revenue of USD 3.7 billion, recovering from a 2024 nationalist boycott campaign over its packaging design. Wantai's subsidiary Xiamen Innovax Biotech developed the world's first approved hepatitis E vaccine and multiple domestically produced HPV vaccines that have undercut foreign manufacturers' pricing power in China.
Business Relationships
Wantai's vaccine programs were developed in scientific partnership with Xiamen University, which co-developed both the bivalent and nine-valent HPV vaccines through joint research with Xiamen Innovax. Nongfu Spring partnered with German materials company Covestro on a circular economy initiative to upcycle one million polycarbonate water barrels per year.
Ownership
Zhong Shanshan is the controlling shareholder of both companies. He holds an 84.5% stake in Nongfu Spring through investment vehicles Hangzhou Youfu and Yangshengtang, and a 73% stake in Wantai BioPharmaceutical, held directly and through Yangshengtang.
Family & Heirs
Zhong's son, Zhong Shuzi, serves as a non-executive director at Nongfu Spring. Zhong announced in January 2025 that he would commit 40 billion yuan (USD 5.5 billion) to establish Qiantang University, a private research university in Hangzhou. In November 2025, he personally donated 100 million yuan to establish an education fund at Zhuji High School, his hometown school, named for his grandfather.
Evidence
2012-10-01 - 😇 - Hecolin becomes world's first approved hepatitis E vaccine, developed by Wantai's subsidiary Xiamen Innovax
2013-04-17 - 😈 - Nongfu Spring used water quality standards permitting arsenic and cadmium above national tap water limits
2019-12-01 - 😇 - China licenses Cecolin, first domestically developed HPV vaccine, breaking foreign monopoly
2020-01-10 - 😇 - Nongfu Spring and Covestro partner to upcycle 1 million polycarbonate water barrels annually into industrial materials
2021-04-01 - 😈 - Chinese NGO filed public interest lawsuit against Nongfu Spring for illegal deforestation inside Wuyishan National Park
2021-10-19 - 😇 - WHO grants prequalification to Wantai subsidiary Innovax's Cecolin HPV vaccine, enabling UN / Gavi procurement
2025-02-09 - 😇 - Zhong Shanshan commits 40 billion yuan to establish Qiantang University in Hangzhou
2025-04-28 - 😇 - WHO prequalifies Wantai's HIV urine self-test, the world's first, enabling UN procurement
2025-05-30 - 😇 - China approves Wantai's Cecolin 9, first domestically produced nine-valent HPV vaccine
2025-07-16 - 😈 - Nongfu Spring subsidiary purchased New Hampshire property adjacent to drinking water infrastructure, drawing national security review
2025-11-22 - 😇 - Zhong Shanshan personally donates 100 million yuan to establish Zhuji High School education fund
2026-07-06 - 😇 - Nongfu Spring donates 10 million yuan cash plus unlimited emergency drinking water and opens a factory as shelter for Guangxi flood victims
Analysis
Zhong Shanshan's most consequential positive impact has come through Wantai BioPharmaceutical's vaccine and diagnostics pipeline. The world's first hepatitis E vaccine, China's first domestic HPV vaccine, and its 2021 WHO prequalification opened access to UN and Gavi procurement in dozens of countries. The 2025 nine-valent HPV vaccine, priced roughly 60% below the imported alternative, and the 2025 WHO-prequalified HIV urine self-test, the world's first of its kind, extend that record of expanding low-cost access to public health tools.
Nongfu Spring's environmental and consumer safety record includes documented failures. Water quality standards permitting arsenic and cadmium levels above national tap water benchmarks were a consumer safety failure, and the Wuyishan deforestation lawsuit confirmed a willingness to build without environmental permits inside a protected national park. The company's 2025 purchase of a New Hampshire property near local drinking-water infrastructure drew a state investigation; New Hampshire's Attorney General found no laws were broken, though the episode prompted a new state law banning similar purchases by Chinese entities.
Zhong has also directed disaster relief and education philanthropy at scale, including 10 million yuan and unlimited emergency water for 2026 Guangxi flood victims and 100 million yuan to his hometown high school's education fund.
Questions
Will the 40 billion yuan Qiantang University pledge be completed as announced, and what independent accountability mechanisms exist?
Did Nongfu Spring update its water quality standards after the 2013 arsenic and cadmium controversy to meet or exceed national tap water benchmarks?
What is the current status of environmental protections at Nongfu Spring's Wuyishan production site following the 2021 lawsuit?
Redemption Arc
The vaccine and diagnostics pipeline at Wantai BioPharmaceutical continues to expand low-cost global health access, most recently with the 2025 WHO-prequalified HIV urine self-test and the discounted nine-valent HPV vaccine. The Qiantang University pledge and Zhuji education fund donation add substantial philanthropic commitments, and the New Hampshire property purchase was cleared of legal wrongdoing though it remains a live political controversy. The trajectory points toward continued positive contribution provided the environmental and consumer-safety record does not repeat.